Catheter-Directed Thrombolysis Technique for Acute Proximal DVT
Catheter-directed thrombolysis (CDT) involves inserting a multiple side-hole catheter directly into the venous thrombus under imaging guidance and infusing a thrombolytic agent (typically rtPA at 0.01 mg/kg) locally into the clot, often preceded by temporary IVC filter placement and potentially combined with mechanical thrombectomy or stenting. 1
Pre-Procedure Setup
Patient Selection Criteria
- Acute iliofemoral DVT with symptom onset within 10-14 days (success rates decline significantly after this window) 1
- No absolute contraindications to thrombolysis
- Proximal DVT involving iliac and/or femoral veins (not isolated distal DVT)
Initial Steps
- Place temporary IVC filter first - This is standard practice to prevent PE during the procedure, particularly when performing pharmacomechanical thrombectomy 2
- Obtain vascular access - typically via the ipsilateral popliteal vein or alternatively the small saphenous vein 3, 4
- Perform baseline venography to map thrombus extent
The CDT Procedure
Catheter Placement
- Insert a multiple side-hole infusion catheter directly into the thrombus under fluoroscopic or ultrasound guidance 1
- Position the catheter so side holes span the entire length of the thrombus
- Confirm positioning with contrast venography
Thrombolytic Infusion Protocol
Use rtPA (recombinant tissue plasminogen activator) at 0.01 mg/kg - This contemporary dosing has dramatically reduced major bleeding rates from 11.4% with older urokinase regimens to 2% with current rtPA protocols 1
- Continuous infusion: 1 mg/hour rtPA through the catheter 2
- Concurrent unfractionated heparin infusion systemically 3
- Mean duration: 4-5 days of continuous infusion 3
- Monitor fibrinogen levels and coagulation parameters throughout
Pharmacomechanical Enhancement (Optional)
For faster thrombus clearance, combine CDT with mechanical thrombectomy:
- Administer initial bolus of 0.15 mg/kg rtPA via rotational mechanical thrombectomy device 2
- Perform thrombus aspiration or maceration using the catheter 1
- This "single-session PMT" approach uses lower total rtPA doses (median 10 mg vs 20-30 mg for CDT alone) 5
Adjunctive Interventions
When Thrombus Clearance is Inadequate
After CDT, assess residual thrombus:
- Grade III (complete) lysis: 33% of cases - no further intervention needed 3
- Grade II (50-90% lysis): 67% of cases - consider additional procedures 3
For significant residual lesions or underlying stenosis:
- Percutaneous transluminal angioplasty alone if no severe stenosis remains 3
- Venous stenting for persistent iliac vein compression (present in 53% of iliofemoral DVT cases) 5
Post-Procedure Management
- Continue therapeutic anticoagulation indefinitely during and after the procedure
- Remove temporary IVC filter once thrombolysis complete and patient stabilized
- Transition to oral anticoagulation (DOACs preferred) for long-term therapy
Critical Safety Considerations
Bleeding Risk Management
Major bleeding occurs in 1.7-2% with contemporary rtPA protocols 1, 6 - dramatically lower than the 11.4% seen with older urokinase regimens. However:
- Minor bleeding (primarily hematuria) occurs in 32% of patients 2
- Avoid systemic thrombolysis - it increases major bleeding to 14% without improving outcomes and is explicitly not recommended 1
- Monitor for intracranial hemorrhage, which remains a serious risk
When NOT to Perform CDT
The 2021 CHEST guidelines recommend AGAINST routine CDT for most proximal DVT patients 7. The landmark ATTRACT trial (692 patients) showed:
- No reduction in overall post-thrombotic syndrome (47% vs 48%, P=0.56) 6
- No improvement in quality of life 6
- Increased major bleeding (1.7% vs 0.3%, P=0.049) 6
- Only modest reduction in moderate-to-severe PTS (18% vs 24%, P=0.04) 6
Clinical Outcomes
Success Rates
- Technical success: 88-89% achieve successful fibrinolysis 1, 3
- Venous patency at 6 months: 64% vs 36% with anticoagulation alone 1
- Freedom from re-thrombosis: 96% at 3 months, 93% at 6 months, 86% at 12 months 2
Long-Term Benefits
- Reduced functional venous obstruction: 20% vs 49% with anticoagulation alone 1
- Lower PTS incidence: 17.9% vs 51.9% in some studies 4, though ATTRACT showed minimal overall benefit 6
- No difference in femoropopliteal venous reflux 1
Key Pitfalls to Avoid
- Don't use systemic thrombolysis - Transfer patient to center with endovascular expertise rather than attempting systemic lysis 1
- Don't exceed 10-14 day symptom window - Success rates decline significantly with older thrombus 1
- Don't use outdated urokinase protocols - Modern rtPA at 0.01 mg/kg has 5-fold lower bleeding rates 1
- Don't perform CDT routinely - Reserve for highly selected patients given ATTRACT trial results showing no overall PTS benefit 7, 6
The procedure should only be performed at centers with endovascular expertise, and patient selection must be rigorous given the lack of mortality or quality-of-life benefit demonstrated in the largest randomized trial. 7, 6